Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: TQB2440 injection + Trastuzumab + Docetaxel|DRUG: Perjeta + Trastuzumab + Docetaxel
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.